Logo
x

Search

Subscribe Now

Polyneuropathy

Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

  • October 28, 2021
Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy

Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy

  • January 8, 2021
Alnylam's Vutrisiran Receives the US FDA's Fast Track Designation to Treat Polyneuropathy of hATTR Amyloidosis

Alnylam's Vutrisiran Receives the US FDA's Fast Track Designation to Treat Polyneuropathy of hATTR Amyloidosis

  • April 14, 2020
Alnylam Reports Submission of MAA to Brazilian Health Regulatory Agency for Onpattro (patisiran) to Treat Hereditary ATTR Amyloidosis with Polyneuropathy

Alnylam Reports Submission of MAA to Brazilian Health Regulatory Agency for Onpattro (patisiran) to Treat Hereditary ATTR Amyloido...

  • October 11, 2019
Ionis' Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Ionis' Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

  • October 5, 2018
FDA Approves Onpattro- a Novel RNAi Therapeutic to Treat Polyneuropathy in Adults

FDA Approves Onpattro- a Novel RNAi Therapeutic to Treat Polyneuropathy in Adults

  • August 10, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.